Suzhou Ribo Life Science (HKG:6938) achieved the first candidate drug nomination milestone under a licensing agreement with Madrigal Pharmaceuticals, according to a Thursday filing.
The milestone is to advance cutting-edge RNA therapeutics for liver diseases, with a focus on metabolic dysfunction-associated steatohepatitis.
The parties will immediately initiate IND-enabling studies to support planned clinical studies.